Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 29,141 shares, a growth of 183.7% from the November 30th total of 10,272 shares. Based on an average trading volume of 122,940 shares, the short-interest ratio is presently 0.2 days. Currently, 0.6% of the company’s stock are sold short. Currently, 0.6% of the company’s stock are sold short. Based on an average trading volume of 122,940 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Revelation Biosciences in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Revelation Biosciences Price Performance

Shares of REVB opened at $0.86 on Friday. Revelation Biosciences has a 1 year low of $0.83 and a 1 year high of $60.48. The stock has a 50 day simple moving average of $1.02 and a two-hundred day simple moving average of $1.84. The firm has a market cap of $5.09 million, a P/E ratio of -0.03 and a beta of -0.11.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($1.77) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.43). On average, equities analysts anticipate that Revelation Biosciences will post -49.33 earnings per share for the current year.

Hedge Funds Weigh In On Revelation Biosciences

An institutional investor recently bought a new position in Revelation Biosciences stock. Armistice Capital LLC bought a new stake in shares of Revelation Biosciences, Inc. (NASDAQ:REVB) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $114,000. Armistice Capital LLC owned 0.52% of Revelation Biosciences as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.80% of the company’s stock.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.